EP Patent

EP3192502A1 — Pharmaceutical composition of selexipag

Assigned to Sandoz AG · Expires 2017-07-19 · 9y expired

What this patent protects

The present invention relates to an amorphous solid dispersion comprising selexipag and methods for preparing the same. The invention also concerns a pharmaceutical composition comprising an effective amount of said amorphous solid dispersion and at least one further pharmaceutic…

USPTO Abstract

The present invention relates to an amorphous solid dispersion comprising selexipag and methods for preparing the same. The invention also concerns a pharmaceutical composition comprising an effective amount of said amorphous solid dispersion and at least one further pharmaceutically acceptable. The pharmaceutical composition of the present invention may be used as a medicine in particular for the treatment of pulmonary arterial hypertension.

Drugs covered by this patent

Patent Metadata

Patent number
EP3192502A1
Jurisdiction
EP
Classification
—
Expires
2017-07-19
Drug substance claim
No
Drug product claim
No
Assignee
Sandoz AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.